Showing 1 to 2 of 2 results


Halozyme Sues Merck Over Injectable Keytruda
Merck's new injectable Keytruda faces a lawsuit from Halozyme, delaying its planned October 1 launch and highlighting upcoming patent expirations in 2028. The suit challenges Merck's use of Halozyme's hyaluronidase technology in the new injectable formulation, and Merck has said it is meritless.
Halozyme Sues Merck Over Injectable Keytruda
Merck's new injectable Keytruda faces a lawsuit from Halozyme, delaying its planned October 1 launch and highlighting upcoming patent expirations in 2028. The suit challenges Merck's use of Halozyme's hyaluronidase technology in the new injectable formulation, and Merck has said it is meritless.
Progress
40% Bias Score

Oryzon Genomics Raises €30 Million, Bolsters Nasdaq Bid
Oryzon Genomics, a Spanish pharmaceutical company, raised €30 million in an accelerated capital increase led by a US institutional investor, exceeding its initial target, to support its potential Nasdaq dual listing and advance its clinical programs.

Oryzon Genomics Raises €30 Million, Bolsters Nasdaq Bid
Oryzon Genomics, a Spanish pharmaceutical company, raised €30 million in an accelerated capital increase led by a US institutional investor, exceeding its initial target, to support its potential Nasdaq dual listing and advance its clinical programs.
Progress
44% Bias Score
Showing 1 to 2 of 2 results